ASCO, CSCO Outline Best Practices for Nasopharyngeal Carcinoma medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
CARY, N.C., Jan. 27, 2021 /PRNewswire/ After more than two decades of dedication to advance the prevention, diagnosis, and treatment of cancer, Dr. Martin J. Murphy has retired from the Board of Directors of the CEO Roundtable on Cancer. The Board immediately elected him Director Emeritus.
Dr. Murphy was instrumental in launching the CEO Roundtable on Cancer in 2001 at the request of President George H.W. Bush who challenged him to engage action-oriented chief executives to do something more about cancer prevention, diagnosis, and treatment within your own family as well as within your corporate family.
[December 28, 2020]
Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List
SHANGHAI, China, Dec. 29, 2020 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug List (NRDL) (2020 Edition) for the treatment of melanoma by the China National Healthcare Security Administration (NHSA). The primary drug format specification is the 80mg(2ml)/vial. Toripalimab is the only anti-PD-1 monoclonal antibody for the treatment of melanoma that has been included in the NRDL.
Melanoma is an aggressive form of solid tumor with a rapid systemic dissemination. Toripalimab received a conditional approval by the NMPA for the 2